Coeptis Therapeutics Rewards CEO and Closes Series A Sale
Company Announcements

Coeptis Therapeutics Rewards CEO and Closes Series A Sale

Coeptis Therapeutics Holdings (COEP) has issued an announcement.

The Company’s Compensation Committee and Board of Directors have approved a significant incentive for CEO David Mehalick, awarding him options to acquire 2.4 million shares at the closing price on the date of approval, vested immediately with a 10-year term. Additionally, the firm announced the successful closure of their Series A Preferred sale in a recent press release.

See more data about COEP stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyCoeptis Therapeutics expands license agreement with Deverra
TheFlyCoeptis Therapeutics regains Nasdaq compliance
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App